Event info
Date:08 Dec
Time:14:00- 15:00
Contact person


This is an external event. If you have any questions please follow the sign up link and contact the organizer.

Plasmid DNA and Advanced Therapies: Accelerating Path to Clinic

Join industry experts to learn more about the current plasmid DNA manufacturing landscape, development challenges, and the key considerations during plasmid production.

Gene therapies and emerging biomodalities are developing at an unprecedented pace, improving the lives of patients around the world. The high demand for those treatments opens a competitive market in which faster and high-quality cost-effective solutions are a clear advantage. The starting point for advanced therapies is generally DNA in the shape of plasmid DNA (pDNA). GMP requirements from early stage, together with the right tools and analytics providing the highest quality standards for pDNA, will ensure successful downstream applications as AAV, from early clinical development to commercial phase.
Join this webinar for an in-depth discussion of the challenges CGT innovators face and how experts resolve these barriers through adopting technology and strategy that drive an optimized plasmid production process and supply.

Key learning objectives

  • Learn the current plasmid DNA manufacturing landscape.
  • Discuss key considerations during plasmid production, including design and screening system and processing.
  • Discuss the main challenges linked to GMP pDNA production and the impact on different advanced therapy programs.

Date: Thursday 8th of December 2022
Time: 14:00-15:00 CET
Venue: Virtual Webinar in collaboration with BioWin


Name and email for the contact person: Sayali Bendkhale – Sayali.bendkhale@catalent.com



 Eli Keshavarz-Moore, MSc, Ph.D, FIChemE, CEng
Professor of Bioprocess Science and Enterprise, Department of Biochemical Engineering, University College London.
The central theme of Prof. Eli Keshavarz-Moore’s research has been to investigate the interaction between cell engineering and fermentation and downstream processing. The early focus was on the impact of recombinant technology on the processing of macromolecules; in particular proteins with specific attention to the way fermentation strategy may control the location of the protein, and its titre in order to adapt the best harvesting strategy and enable the provision of generic process options for downstream separation. Her research has been the basis for further study on creating a framework for rapid choice of a whole bioprocess prior to detailed design. She brought a new theme based on the specific, knowledge-based design of cells and their propagation in bioreactors in response to the needs and demands of downstream/ purification stages.
 Nuria Gomez Santos, Ph.D
Head of Process & Analytical Development, pDNA.
Dr. Santos is the Head of Process and Analytical Development for plasmid DNA at Catalent Gene Therapy. With a strong expertise in molecular biology and microbiology, acquired through international experience in different research institutions for more than 15 years, she has developed her career in plasmid DNA bioproduction during the last 4 years. Nuria holds two BScs, one in Biology and another in Biochemistry, an MSc in Biotechnology, and a Ph.D. in Microbiology.
 Thierry Ferain,
Director of Innovation & Growth, BioWin.
BioWin is the Health Cluster of Wallonia, Belgium. We are the regional reference holder for all stakeholders in innovative R&I projects in health biotechnology and medical technologies, whether they are companies, research centers, or universities. We also aim to promote Wallonia internationally as a world-class life sciences environment for academic, clinical, and industrial research.


Organized by
In collaboration with